Navigation Links
Greater Efficacy on Cognition and Function Over Current Treatments Remain Neurologists' Top Unmet Need in Mild to Moderate Alzheimer's Disease
Date:9/23/2013

BURLINGTON, Mass., Sept. 23, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that drugs offering a greater effect on cognition and those offering a greater effect on function compared with current treatments remain the top unmet needs in the treatment of mild to moderate Alzheimer's disease (AD), according to surveyed U.S. and European neurologists. Currently available therapies alleviate some cognitive and functional symptoms associated with AD over the short-term, but do not slow disease progression, thus underscoring the remaining unmet need for more efficacious alternatives, which could be either symptomatic or disease-modifying.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase report entitled Alzheimer's Disease (Mild to Moderate): In an Increasingly Generic Market, What Attributes Can Differentiate Novel Brands in the Minds of Physicians and Payers? also finds that, based on a product profile presented, surveyed U.S. neurologists would prescribe Eli Lilly's emerging anti-beta-amyloid monoclonal antibody solanezumab to a median 15 percent of their mild to moderate AD patients. Interviewed thought leaders are encouraged by a slowing of cognitive decline observed in solanezumab-treated mild AD patients, pooled across two completed, placebo-controlled, Phase III studies, as well as the drug's safety profile, particularly with regard to a low risk of amyloid-related imaging abnormalities.

The report also includes insights from a survey of U.S. managed care organization pharmacy directors, two-thirds of whom indicate they would reimburse a new disease-modifying therapy for the treatment of mild to moderate AD that was priced at a significant premium to current brands ($25/day), if such an agent offered a 200 percent improvement on cognitive decline over donepezil (Eisai/Pfizer's Aricept, other brands, generics). Payers expecting not to cover such a therapy mostly cite insufficient benefits as the reason, suggesting that—for some payers—greater therapeutic gains would be needed to justify the value of a drug offered at such a considerable cost.

"With a new Phase III trial ongoing in mild AD, solanezumab retains the potential to become the first disease-modifying therapy approved for the treatment of this debilitating disease, a landmark achievement," said Decision Resources Senior Business Insights Analyst Alana Simorellis, Ph.D. "We expect solanezumab likely would be priced much higher than symptomatic brands today, which could present challenges to usage and market access, depending on the level of its clinical benefits. Even with limited uptake, however, we expect premium pricing and a growing patient population could easily drive blockbuster sales for solanezumab in the AD market over the next decade."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Diagnostic Imaging Releases Recommendations For Greater Reading Room Comfort
2. End Users Desire for Greater Control over Production Processes Increases Adoption of SISs in Europe, Finds Frost & Sullivan
3. NxStage Urges CMS to Fix Training Reimbursement to Provide Medicare Patients Greater Access to Life-Changing Home Hemodialysis Therapies
4. Novel LABA/LAMA Products Will Capture Greater Market Share than the LABA/ICS or LAMA Drug Classes by 2022
5. CPhI Report Indicates a Need for Greater Third Party Certification to Ensure GMP Vigilance
6. Mitsubishi Chemical Medience and LabCorp Clinical Trials Announce Master Service Agreement to Offer Clients Greater Access to Global Central Lab Services
7. A Greater Effect on Depressive Symptoms than Current Treatments is One of the Greatest Unmet Needs in Treatment-Resistant Depression
8. Smart911 and In Case of Emergency Standard Partner to Enhance Availability of Life Saving Data for Greater Emergency Response
9. Cancer drug shortages mean higher costs and greater risk for patients
10. New Report Details NCPA Efforts to Drive Greater Medication Adherence
11. Greater New York Dental Meeting and Inside Dental Technology Announce Collaboration 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... N.J. , June 24, 2016  Collagen ... the design, development and manufacturing of collagen and ... regeneration announced today that Bill Messer ... and Marketing to further leverage the growing portfolio ... medical devices. Bill joins the Collagen ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
Breaking Medicine News(10 mins):